Fhit, a tumor suppressor protein, induces autophagy via 14-3-3τ in non-small cell lung cancer cells
Metrics: PDF 705 views | HTML 1381 views | ?
Tae-Gul Lee1,2, Eun-Hui Jeong1, Seo Yun Kim1, Hye-Ryoun Kim1, Hyunggee Kim2, Cheol-Hyeon Kim1
1Division of Pulmonology, Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Korea
2School of Life Sciences and Biotechnology, Korea University, Seoul, Korea
Cheol-Hyeon Kim, email: email@example.com
Keywords: Fhit, autophagy, 14-3-3τ, non-small cell lung cancer, apoptosis
Received: September 23, 2016 Accepted: March 16, 2017 Published: March 29, 2017
Inactivation of the fragile histidine triad (Fhit) gene has been reported in the majority of human cancers, particularly in lung cancer. The role of Fhit as a tumor suppressor gene has been well documented, and restoration of Fhit expression suppresses tumorigenicity in tumor cell lines and in mouse models by inducing apoptosis and inhibiting proliferation of tumor cells. Autophagy is a catabolic pathway, whereby cytoplasmic proteins and organelles are sequestered in vacuoles and delivered to lysosomes for degradation and recycling. Although autophagy is necessary for cell survival under stress conditions, recent studies have shown that autophagy can also promote cell death. Due to the fact that both autophagy induction and Fhit expression are commonly associated with nutrient starvation, we hypothesized that Fhit expression may be related to autophagy induction. In the present study, we assessed whether Fhit overexpression by gene transfer induces autophagy in Fhit-deficient non-small cell lung cancer (NSCLC) cells. The results of our study indicate that Fhit protein induces autophagy in NSCLC cells, and that this autophagy prevents apoptotic cell death in vivo and in vitro in a 14-3-3τ protein-dependent manner. To the best of our knowledge, this is the first report to describe Fhit-induced autophagy. Suppressing autophagy might be a promising therapeutic option to enhance the efficacy of Fhit gene therapy in NSCLC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.